In the last few months, covid-19 has spread as a highly contagious pandemic. Currently no therapies have proven to be effective for the treatment of this severe illness that progresses with a strong inflammation in different organs and systems. Because fibroblast growth factor (FGF) is a potent inflammatory agent, we have tested, in one patient who didnt respond to the protocol therapy, the effect of FGF inhibition with an anti-inflammatory and antiviral compound with a large history of medical use which was reported as the most effective anti-FGF inhibitor: dobesilate. After five days of oral treatment, dobesilate resulted in amelioration of chest radiographies as well as in clinical improvement, opening a new possible therapeutic mean to be tested in patients.
Key words: Covid-19 infection, fibroblast growth factor, dobesilate
|
